We are thrilled to introduce you to BioLoomics, a new partner in our urgent mission to find treatments for KIF1A-Associated Neurological Disorder (KAND). BioLoomics uses their technology to speed up therapeutic discovery and yield promising drugs that cannot be found through traditional approaches. As we work relentlessly to outpace the ticking clock of neurodegeneration, we are grateful to the team at BioLoomics for joining our mission to bring treatment to this generation of people affected by KAND.
We have no time to waste. Every day we go without KAND treatment, our children and friends affected by KAND are at risk of losing their mobility, sight, speech, independence, and even their lives. KIF1A.ORG works with a sense of urgency that we recognize in the BioLoomics team. Their “evolution-in-a-microscope” VariVolve Platform technology will build the high throughput drug discovery tools we need to accelerate the pace of discovery.
To learn more about BioLoomics and our partnership, check out this announcement and visit https://bioloomics.com/. Make sure you’re registered to attend the virtual 2021 KAND Family & Scientific Engagement Conference on July 9-10, where BioLoomics CEO & Founder Dr. Douglas Chapnick will present on their KIF1A program and take questions from the audience.
Thank you to the BioLoomics team for leveraging your powerful technology and innovative approaches to help KIF1A.ORG improve the lives of KAND patients and their families!